About Aurinia Pharmaceuticals Inc.
https://www.auriniapharma.comAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
CEO
Peter S. Greenleaf
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-11-08 | Reverse | 1:50 |
| 2013-10-23 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 3 of 107
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
TANG CAPITAL MANAGEMENT LLC
Shares:11.33M
Value:$172.55M
BLACKROCK INC.
Shares:9.27M
Value:$141.22M
BLACKROCK, INC.
Shares:7.45M
Value:$113.45M
Summary
Showing Top 3 of 280
About Aurinia Pharmaceuticals Inc.
https://www.auriniapharma.comAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $73.47M ▲ | $35.22M ▼ | $31.55M ▲ | 42.95% ▲ | $0.24 ▲ | $36.83M ▲ |
| Q2-2025 | $70.01M ▲ | $42.81M ▲ | $21.51M ▼ | 30.73% ▼ | $0.16 | $28.14M ▼ |
| Q1-2025 | $62.47M ▲ | $32.04M ▼ | $23.34M ▲ | 37.37% ▲ | $0.16 ▲ | $30.27M ▲ |
| Q4-2024 | $59.87M ▼ | $55.98M ▲ | $1.43M ▼ | 2.39% ▼ | $0.01 ▼ | $7.18M ▼ |
| Q3-2024 | $67.77M | $49.99M | $14.35M | 21.17% | $0.1 | $20.91M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $351.81M ▲ | $527.53M ▲ | $161.76M ▼ | $365.77M ▲ |
| Q2-2025 | $315.13M ▲ | $502.56M ▼ | $167.26M ▲ | $335.3M ▼ |
| Q1-2025 | $312.9M ▼ | $504.85M ▼ | $154.66M ▼ | $350.19M ▼ |
| Q4-2024 | $358.48M ▲ | $550.64M ▲ | $173.17M ▲ | $377.48M ▼ |
| Q3-2024 | $348.75M | $549.36M | $161.36M | $388M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $31.55M ▲ | $44.45M ▲ | $-13.77M ▼ | $-10.49M ▲ | $20.19M ▲ | $44.38M ▲ |
| Q2-2025 | $21.51M ▼ | $44.24M ▲ | $-13.27M ▼ | $-44.39M ▲ | $-13.43M ▲ | $44.14M ▲ |
| Q1-2025 | $23.34M ▲ | $1.3M ▼ | $31.03M ▼ | $-49.34M ▼ | $-17M ▼ | $1.28M ▼ |
| Q4-2024 | $1.43M ▼ | $30.11M ▲ | $39.22M ▲ | $-23.05M ▼ | $46.29M ▲ | $30.06M ▲ |
| Q3-2024 | $14.35M | $17.03M | $-10.57M | $-2.72M | $3.73M | $16.94M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 License Collaboration and Royalty Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $60.00M ▲ | $70.00M ▲ | $60.00M ▼ | $70.00M ▲ |
CEO
Peter S. Greenleaf
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-11-08 | Reverse | 1:50 |
| 2013-10-23 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 3 of 107
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
TANG CAPITAL MANAGEMENT LLC
Shares:11.33M
Value:$172.55M
BLACKROCK INC.
Shares:9.27M
Value:$141.22M
BLACKROCK, INC.
Shares:7.45M
Value:$113.45M
Summary
Showing Top 3 of 280